89 results
424B3
PRE
Prenetics Global Limited - Ordinary Shares
16 Feb 24
Prospectus supplement
6:13am
business successfully with ACT Genomics and realize the anticipated synergies and related benefits, or to do so within the anticipated timeframe … the anticipated synergies and related benefits of the ACT Acquisition or do so within the anticipated timeframe.
Our acquisition may not be accretive
F-3
PRE
Prenetics Global Limited - Ordinary Shares
17 Jan 24
Shelf registration (foreign)
6:59am
and realize the anticipated synergies and related benefits, or to do so within the anticipated timeframe.
The forward-looking statements contained … as a result of the ACT Acquisition and may be unable to integrate our businesses successfully and realize the anticipated synergies and related benefits
F-3
EX-3.1
PRE
Prenetics Global Limited - Ordinary Shares
17 Jan 24
Shelf registration (foreign)
6:59am
Share in the capital of the Company of a par value of US$0.0001 having the rights, benefits and privileges set out in these Articles; Class B Ordinary … Share means a Class B Ordinary Share in the capital of the Company of a par value of US$0.0001 having the rights, benefits and privileges set out
F-3
EX-10.25
PRE
Prenetics Global Limited - Ordinary Shares
17 Jan 24
Shelf registration (foreign)
6:59am
the Exchange Act. With a view to making available to the Investor the benefits of Rule 144, the Company agrees to: 8.1.1 use its commercially reasonable efforts … . This Agreement shall not confer any rights or benefits on any Persons that are not parties hereto, other than as expressly set forth in this Agreement
424B3
PRE
Prenetics Global Limited - Ordinary Shares
2 Nov 23
Prospectus supplement
4:04pm
and related benefits, or to do so within the anticipated timeframe.
The forward-looking statements contained in this prospectus are based on our current … synergies and related benefits of the ACT Acquisition or do so within the anticipated timeframe.
Our acquisition may not be accretive, and may
POS AM
yepvpb2j
6 Oct 23
Prospectus update (post-effective amendment)
1:52pm
F-3
j8v0an6dnt5k66ui911z
29 Sep 23
Shelf registration (foreign)
9:17am
424B3
y5ekdlr5 7rwz
21 Jul 23
Prospectus supplement
6:16am
CORRESP
m96g9 0664peptg1r4yu
14 Jul 23
Correspondence with SEC
12:00am
POS AM
y21 d9bslh
6 Jul 23
Prospectus update (post-effective amendment)
9:00am
POS AM
EX-10.24
ny51euwl3hc6c1o324uq
6 Jul 23
Prospectus update (post-effective amendment)
9:00am
POS AM
EX-10.23
ayp4qhefum37v7w5
6 Jul 23
Prospectus update (post-effective amendment)
9:00am
6-K
EX-99.1
1ix 4g4ffu
26 Jun 23
Current report (foreign)
8:45am
POS AM
j327vzaqw2t2lc
31 May 23
Prospectus update (post-effective amendment)
8:25am
POS AM
nb30s1pg 7c
1 May 23
Prospectus update (post-effective amendment)
5:19pm
POS AM
29mjcwhcc9uoh0ecto5
14 Dec 22
Prospectus update (post-effective amendment)
8:04am
424B3
1q2483 oh
1 Jul 22
Prospectus supplement
4:10pm